These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27818661)

  • 1. The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.
    Apostolova P; Zeiser R
    Front Immunol; 2016; 7():439. PubMed ID: 27818661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells during Graft-versus-Host Disease.
    Klämbt V; Wohlfeil SA; Schwab L; Hülsdünker J; Ayata K; Apostolova P; Schmitt-Graeff A; Dierbach H; Prinz G; Follo M; Prinz M; Idzko M; Zeiser R
    J Immunol; 2015 Dec; 195(12):5795-804. PubMed ID: 26538394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of danger signals and ectonucleotidases in acute graft-versus-host disease.
    Apostolova P; Zeiser R
    Hum Immunol; 2016 Nov; 77(11):1037-1047. PubMed ID: 26902992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation.
    Ramadan A; Paczesny S
    Front Immunol; 2015; 6():14. PubMed ID: 25674088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.
    Toubai T; Mathewson ND; Magenau J; Reddy P
    Front Immunol; 2016; 7():539. PubMed ID: 27965667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Danger signals activating innate immunity in graft-versus-host disease.
    Zeiser R; Penack O; Holler E; Idzko M
    J Mol Med (Berl); 2011 Sep; 89(9):833-45. PubMed ID: 21573893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
    Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
    J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.
    Lamarthée B; Malard F; Saas P; Mohty M; Gaugler B
    Front Immunol; 2016; 7():148. PubMed ID: 27148267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heme as a danger molecule in pathogen recognition.
    Wegiel B; Hauser CJ; Otterbein LE
    Free Radic Biol Med; 2015 Dec; 89():651-61. PubMed ID: 26456060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
    Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
    Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR.
    Mapara MY; Leng C; Kim YM; Bronson R; Lokshin A; Luster A; Sykes M
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):623-34. PubMed ID: 16737935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors.
    Ferrara JL
    J Hematother Stem Cell Res; 2000 Jun; 9(3):299-306. PubMed ID: 10894351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Damage/Danger Associated Molecular Patterns (DAMPs) Modulate Chlamydia pecorum and C. trachomatis Serovar E Inclusion Development In Vitro.
    Leonard CA; Schoborg RV; Borel N
    PLoS One; 2015; 10(8):e0134943. PubMed ID: 26248286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the IL17 pathway for the prevention of graft-versus-host disease.
    van der Waart AB; van der Velden WJ; Blijlevens NM; Dolstra H
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):752-9. PubMed ID: 24565991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight into the mechanisms regulating immune homeostasis in health and disease.
    Sirisinha S
    Asian Pac J Allergy Immunol; 2011 Mar; 29(1):1-14. PubMed ID: 21560483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release.
    Im KI; Kim N; Lim JY; Nam YS; Lee ES; Kim EJ; Kim HJ; Kim SH; Cho SG
    J Immunol; 2015 Jun; 194(11):5223-32. PubMed ID: 25911749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.